Results 161 to 170 of about 198,722 (342)

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report [PDF]

, 2019
Callebout, Eduard, Claes, Kathleen, De Man, Marc, Ferdinande, Liesbeth, Geboes, Karen, Laurent, Stéphanie, Moura Ribeiro, Suzane, Van der Meulen, Joni   +7 more
core   +2 more sources

BRAF [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature, 2022
C. Vellano, M. G. White, M. Andrews, M. Chelvanambi, R. Witt, J. Daniele, M. Titus, J. McQuade, F. Conforti, E. Burton, Matthew Lastrapes, G. Ologun, Alexandria P. Cogdill, Golnaz Morad, P. Prieto, A. Lazar, Yanshuo Chu, Guangchun Han, M. A. Khan, Beth A. Helmink, M. Davies, R. Amaria, Jeffrey J Kovacs, S. Woodman, S. Patel, P. Hwu, M. Peoples, Jeffrey E. Lee, Z. Cooper, Haifeng Zhu, G. Gao, H. Banerjee, M. Lau, J. Gershenwald, A. Lucci, E. Keung, M. Ross, L. Pala, E. Pagan, R. Segura, Qian Liu, Mikayla S. Borthwick, Eric K. Lau, M. Yates, S. Westin, K. Wani, M. Tetzlaff, L. Haydu, Mikhila Mahendra, Xiaoyan Ma, Christopher Logothetis, Zachary J Kulstad, Sarah B. Johnson, C. Hudgens, Ningping Feng, L. Federico, G. Long, P. Futreal, Swathi Arur, H. Tawbi, Amy E. Moran, Linghua Wang, T. Heffernan, J. Marszalek, J. Wargo   +64 more
semanticscholar   +1 more source

Clinical implications of PD‐L1 expression in oncogene‐driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors

International Journal of Cancer, EarlyView.
What's New? PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in patients with non‐small‐cell lung cancer lacking oncogenic driver mutations. However, its significance in patients with driver mutations remains unclear. In this study of 273 patients with stage IV non–‐small‐cell lung cancer harboring diverse driver alterations and PD ...
Xiaoxiao Fan, Chenxi Wei, Minjun Rong, Shengnan Wang, Jiaying Wang, Xiaohan Wang, Xiao Han, Xue Meng   +7 more
wiley   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

The frequency of mutations in advanced thyroid cancer in Japan: a single-center study

Endocrine Journal
We analyzed the outcomes of genetic testing to study the frequency of mutations in advanced thyroid cancer in Japan. Patients (n = 96) with unresectable or metastatic thyroid carcinoma were included for retrospective chart review.
Soji Toda, Hiroyuki Iwasaki, Yoichiro Okubo, Hiroyuki Hayashi, Mei Kadoya, Hiroyuki Takahashi, Tomoyuki Yokose, Yukihiko Hiroshima, Katsuhiko Masudo   +8 more
doaj   +1 more source

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

International Journal of Cancer, EarlyView.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho, Fabio Nunes de Mello, Ana Carolina Tahira, Gabriel Nakanishi Fortes, Agatha Fischer‐Carvalho, Pedro Jardim Poli, Murilo Sena Amaral, Sergio Verjovski‐Almeida   +7 more
wiley   +1 more source

BRAF [PDF]

Science-Business eXchange, 2012
openaire   +1 more source

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

New England Journal of Medicine, 2017
G. Long, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, D. Schadendorf, T. Lesimple, R. Plummer, R. Ji, Pingkuan Zhang, B. Mookerjee, J. Legos, R. Kefford, R. Dummer, J. Kirkwood   +22 more
semanticscholar   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source